StemImmune

StemImmune was a clinical-stage biotechnology company focused on developing a novel approach to cancer immunotherapy by combining oncolytic viruses with stem cell delivery systems. The company's core technology utilized mesenchymal stem cells (MSCs) as 'Trojan horses' to protect and transport oncolytic viruses directly to tumor sites, aiming to overcome the limitations of systemic viral delivery such as neutralization by the immune system. StemImmune's lead programs targeted various solid tumors, including melanoma and breast cancer. In 2019, the company was acquired by Calidi Biotherapeutics, which integrated StemImmune's technology and clinical assets into its own pipeline of cell-based oncolytic virus therapies.